FCCC LOGO Faculty Publications
Beissel B , Silva Idcg , Pesquero JB , Russo J , Schor N , Bellini MH
S-phase reduction in T47D human breast cancer epithelial cells induced by an S100P antisense-retroviral construct
Oncology Reports. 2007 Mar;17(3) :611-615
PMID: ISI:000244207800017   
Back to previous list
Abstract
S100P is expressed in several malignant neoplasms. It was previously demonstrated that S100P is involved in the very early stages of breast carcinogenesis. In the present study we used a retrovirus-mediated transfer of antisenseSIOOP in order to check whether the decrease in expression of this protein could lead to alterations in the cell cycle of epithelial cells of human breast cancer. The T47D breast carcinoma cell line, a human breast epithelial cell that expresses high levels of S100P, was a tool used in this study to investigate the alteration in cell cycle induced by a retrovirus-mediated transfer of antisense-S100P. First we used the real-time PCR technique to quantify the gene expression. The results showed a reduction of 63% of expression within the T47D-S100P-A/S infected population compared with control T47D-LXSN clones. To determine the impact of the SIOOP antisense technique on protein expression in T47D cells, we performed immunofluorescence staining and analyzed the resulting images using a confocal microscope. The images showed much less pronounced antibody marking of the S100P protein in the T47D-SIOOPA/S compared with control cells. To evaluate whether the antisense approach caused any alteration in the cell cycle, we concluded the study with flow cytometric analysis of the cell distribution. Our findings indicated that, in our model, S100P-antisense cells showed a 23 % reduction of cells at the S-phase. Using transduction techniques with an S100P anti sense-retroviral construct we were able to demonstrate a significant reduction in S-phase of the T47D cell cycle. To the best of our knowledge, this is the first time that an antisense approach has been used against S100P mRNA in breast cancer epithelial cells. The results showed here seem to further classify S100P as a protein that might be involved in the cell cycle imbalance observed during breast carcinogenesis.
Notes
ISI Document Delivery No.: 136FK Times Cited: 0 Cited Reference Count: 33 Cited References: AMLER LC, 2000, CANCER RES, V60, P6134 ARUMUGAM T, 2003, J BIOL CHEM, V279, P5059 ARUMUGAM T, 2005, CLIN CANCER RES, V11, P5356 AVERBOUKH L, 1996, PROSTATE, V29, P350 BECKER T, 1992, EUR J BIOCHEM, V207, P541 BEER DG, 2002, NAT MED, V8, P816 BELLINI MH, 2003, FASEB J, V17, P2322 BERTRAM J, 1998, ANTI-CANCER DRUG, V9, P311 CHISAMORE MJ, 2001, CLIN CANCER RES, V7, P3156 CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156 CRNOGORACJURCEVIC T, 2003, J PATHOL, V201, P63 DALESSIO JM, 1988, NUCLEIC ACIDS RES, V16, P1999 DIEDERICHS S, 2004, CANCER RES, V64, P5564 DONATO R, 2001, INT J BIOCHEM CELL B, V33, P637 EMOTO Y, 1992, BIOCHEM BIOPH RES CO, V182, P1246 FILIPEK A, 2002, J BIOL CHEM, V277, P28848 GRIBENKO A, 1998, PROTEIN SCI, V7, P211 GUERREIRO DS, 2000, INT J ONCOL, V16, P231 IACOBUZIODONAHUE CA, 2002, AM J PATHOL, V160, P1239 KOLTZSCHER M, 2003, MOL BIOL CELL, V14, P2372 KOTEWICZ ML, 1988, NUCLEIC ACIDS RES, V16, P265 MICHEA I, 2000, AM J PHYSIOL-RENAL, V278, F209 MOUSSES S, 2002, CANCER RES, V62, P1256 PEINNEQUIN A, 2004, BMC IMMUNOL, V5, P3 SARTORIUS CA, 2003, BREAST CANCER RES TR, V79, P287 SATO N, 2002, ANAT REC, V267, P60 SATO N, 2004, ONCOGENE, V23, P1531 SCHOR APT, 2006, ONCOL REP, V15, P3 TERRIS B, 2002, AM J PATHOL, V160, P1745 VINDELOV LL, 1990, CYTOMETRY, V11, P753 WANG GZ, 2006, CANCER RES, V66, P1199 YANG ES, 2003, J BIOL CHEM, V278, P46862 YANG JC, 2004, J BIOL CHEM, V279, P53915 Beissel, Bettina Silva, Ismael D. C. G. Pesquero, Joao B. Russo, Jose Schor, Nestor Bellini, Maria Helena